Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke
Aim. To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS).Material and methods. 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were ex...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2022-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3390 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250227293257728 |
|---|---|
| author | O. A. Osipova A. N. Ilnitsky E. V. Gosteva S. G. Gorelik L. V. Vasilyeva N. I. Klyushnikov N. I. Golovina Yu. V. Tatarintseva Yu. A. Lykov |
| author_facet | O. A. Osipova A. N. Ilnitsky E. V. Gosteva S. G. Gorelik L. V. Vasilyeva N. I. Klyushnikov N. I. Golovina Yu. V. Tatarintseva Yu. A. Lykov |
| author_sort | O. A. Osipova |
| collection | DOAJ |
| description | Aim. To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS).Material and methods. 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were examined. Patients were randomly divided into pharmacotherapy groups: 47 patients took telmisartan (80 mg/day) and 45 — perindopril (10 mg/day). Fasting plasma glucose levels, insulin, leptin, total cholesterol, triglycerides, highand lowdensity lipoprotein cholesterol were determined, the HOMA-IR index was calculated, and daily monitoring was performed. Statistical processing was carried out using STATISTICA 10,0. The indicators are presented in the form of the median, interquartile ranges of Me (Q25%; Q75%), and mean ±SD. The comparison was carried out using the Wilcoxon rank criterion. The differences are significant at p<0,05.Results. After 12 months of observation in the telmisartan group, there was a significant decrease in the average daily systolic blood pressure (ВРs) from 152 (146; 156) to 129 (125; 134) mm Hg (p<0,01) and diastolic blood pressure from 89 (83; 96) to 76 (72; 84) mm Hg (p<0,05); reduction of НOMА-IR from 4,1 (3,3; 5,0) to 3,2 (2,7; 3,6) units (p<0,01), leptin from 14,3 (10,2; 17,7) to 11,7 (10,8; 13,6) ng/ml (p<0,01), triglycerides from 2,25 (1,90; 2,53) up to 2,05 (1,84; 2,05) mmol/l (p<0,05). In the perindopril group, ВРs decreased from 149 (144; 154) to 137 (131; 142) mm Hg (p<0,05), НOMА-IR (p=0,059), leptin from 14,4 (10,3; 18,0) to 13,0 (12,3; 13,8) ng/ml (p<0,05), triglycerides (p=0,056).Conclusion. Elderly patients with hypertension on the background of MS and a history of IS had significantly decreased ВРs and ВРd (according to the results of daily monitoring) after 12 months of telmisartan pharmacotherapy, decreased insulin resistance and the level of leptin and triglycerides in the blood serum. |
| format | Article |
| id | doaj-art-aec743bded234db2a7b1989bd8f01cf2 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2022-10-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-aec743bded234db2a7b1989bd8f01cf22025-08-20T03:57:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252022-10-0121910.15829/10.15829/1728-8800-2022-33902555Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic strokeO. A. Osipova0A. N. Ilnitsky1E. V. Gosteva2S. G. Gorelik3L. V. Vasilyeva4N. I. Klyushnikov5N. I. Golovina6Yu. V. Tatarintseva7Yu. A. Lykov8Belgorod State National Research UniversityBelgorod State National Research University; Institute of Advanced Training of the FMBABelgorod State National Research University; N. N. Burdenko Voronezh State Medical UniversityBelgorod State National Research UniversityN. N. Burdenko Voronezh State Medical UniversityVoronezh City Clinical Hospital of emergency medical care № 8Belgorod State National Research UniversityBelgorod State National Research UniversityBelgorod State National Research UniversityAim. To compare the effectiveness of telmisartan and perindopril in the treatment of elderly patients with arterial hypertension (AH) and metabolic syndrome (MS) who have suffered ischemic stroke (IS).Material and methods. 92 elderly patients with AH and MS who underwent IS (mean 68±4 years) were examined. Patients were randomly divided into pharmacotherapy groups: 47 patients took telmisartan (80 mg/day) and 45 — perindopril (10 mg/day). Fasting plasma glucose levels, insulin, leptin, total cholesterol, triglycerides, highand lowdensity lipoprotein cholesterol were determined, the HOMA-IR index was calculated, and daily monitoring was performed. Statistical processing was carried out using STATISTICA 10,0. The indicators are presented in the form of the median, interquartile ranges of Me (Q25%; Q75%), and mean ±SD. The comparison was carried out using the Wilcoxon rank criterion. The differences are significant at p<0,05.Results. After 12 months of observation in the telmisartan group, there was a significant decrease in the average daily systolic blood pressure (ВРs) from 152 (146; 156) to 129 (125; 134) mm Hg (p<0,01) and diastolic blood pressure from 89 (83; 96) to 76 (72; 84) mm Hg (p<0,05); reduction of НOMА-IR from 4,1 (3,3; 5,0) to 3,2 (2,7; 3,6) units (p<0,01), leptin from 14,3 (10,2; 17,7) to 11,7 (10,8; 13,6) ng/ml (p<0,01), triglycerides from 2,25 (1,90; 2,53) up to 2,05 (1,84; 2,05) mmol/l (p<0,05). In the perindopril group, ВРs decreased from 149 (144; 154) to 137 (131; 142) mm Hg (p<0,05), НOMА-IR (p=0,059), leptin from 14,4 (10,3; 18,0) to 13,0 (12,3; 13,8) ng/ml (p<0,05), triglycerides (p=0,056).Conclusion. Elderly patients with hypertension on the background of MS and a history of IS had significantly decreased ВРs and ВРd (according to the results of daily monitoring) after 12 months of telmisartan pharmacotherapy, decreased insulin resistance and the level of leptin and triglycerides in the blood serum.https://cardiovascular.elpub.ru/jour/article/view/3390arterial hypertensionmetabolic syndrometelmisartanperindopril |
| spellingShingle | O. A. Osipova A. N. Ilnitsky E. V. Gosteva S. G. Gorelik L. V. Vasilyeva N. I. Klyushnikov N. I. Golovina Yu. V. Tatarintseva Yu. A. Lykov Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke Кардиоваскулярная терапия и профилактика arterial hypertension metabolic syndrome telmisartan perindopril |
| title | Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke |
| title_full | Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke |
| title_fullStr | Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke |
| title_full_unstemmed | Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke |
| title_short | Advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke |
| title_sort | advantages of telmisartan pharmacotherapy in elderly patients with arterial hypertension and metabolic syndrome who have suffered an ischemic stroke |
| topic | arterial hypertension metabolic syndrome telmisartan perindopril |
| url | https://cardiovascular.elpub.ru/jour/article/view/3390 |
| work_keys_str_mv | AT oaosipova advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT anilnitsky advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT evgosteva advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT sggorelik advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT lvvasilyeva advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT niklyushnikov advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT nigolovina advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT yuvtatarintseva advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke AT yualykov advantagesoftelmisartanpharmacotherapyinelderlypatientswitharterialhypertensionandmetabolicsyndromewhohavesufferedanischemicstroke |